Drug Trial Radar · NCT04303780
Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).
Last checked: Nov 20, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
345
Actual
Start
Jun 4, 2020
Primary completion
Aug 2, 2022
Study completion Jun 24, 2026
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Mar 11, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 3 Study to Compare AMG 510 with Docetaxel in Non Small Cell Lung Cancer (NSCLC) subjects with KRAS p. G12c mutation
Conditions
- KRAS p, G12c Mutated /Advanced Metastatic NSCLC
Interventions
AMG 510Drug
21 day cycles
DocetaxelDrug
21 day cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS)Time frame: Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months
Locations
274 sites in 23 countries. Site status is shown where the registry gives one.
Pacific Cancer Medical Center Inc
Anaheim, California
City of Hope National Medical Center
Duarte, California
Pacific Shores Medical Group Long Beach
Long Beach, California
University of California Los Angeles
Los Angeles, California
University of California Los Angeles
Los Angeles, California
University of California at Davis Medical Center
Sacramento, California
Ridley Tree Cancer Center
Santa Barbara, California
University of California San Francisco Mission Hall
Stanford, California
Harbor University of California Los Angeles Medical Center
Torrance, California
Rocky Mountain Cancer Centers
Denver, Colorado
Danbury Hospital
Norwalk, Connecticut
Medical Oncology Hematology Consultants Helen F Graham Cancer Center
Newark, Delaware
Washington Cancer Institute at MedStar Washington Hospital
Washington D.C., District of Columbia
Florida Cancer Specialists - Fort Myers
Fort Myers, Florida
Memorial Regional Hospital
Hollywood, Florida
Florida Cancer Specialists Research North
St. Petersburg, Florida
Florida Cancer Specialists Research Panhandle
Tallahassee, Florida
Emory University
Atlanta, Georgia
Northside Hospital, Incorporated
Atlanta, Georgia
Affiliated Oncologists, LLC
North Chicago, Illinois
Fort Wayne Medical Oncology and Hematology
Fort Wayne, Indiana
Willis Knighton Cancer Center
Shreveport, Louisiana
Maryland Oncology Hematology PA
Clinton, Maryland
New York Cancer and Blood Specialists
Lowell, Massachusetts
University of Michigan
Ann Arbor, Michigan
Center for Oncology Clinical Trials
Grand Rapids, Michigan
Minnesota Oncology Hematology PA
Minneapolis, Minnesota
HCA Midwest Health Kansas City
Kansas City, Missouri
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
Summit Medical Group
Florham Park, New Jersey
New York Oncology Hematology, PC
Albany, New York
United States Oncology Regulatory Affairs Corporate Office
Albany, New York
Northwell Health Monter Cancer Center
Lake Success, New York
Montefiore Einstein Center for Cancer Care
The Bronx, New York
James J Peters VA Medical Center
The Bronx, New York
Wake Forest Baptist Health
Winston-Salem, North Carolina
Oncology Hematology Care Inc
Cincinnati, Ohio
Northwest Cancer Specialists - Vancouver
Portland, Oregon
Charleston Oncology
Charleston, South Carolina
Saint Francis Hospital, Inc
Greenville, South Carolina
Showing 40 of 274 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.